10X Genomics, Inc. Hits New 52-Week High at $36.75

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 36.75 on June 25, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 61.09%, significantly outpacing the S&P 500's growth of 20.77% during the same period. The company's market capitalization stands at approximately USD 2,489 million, reflecting its position within the small-cap segment. Despite being loss-making, 10X Genomics has demonstrated resilience in its market performance. The stock's price-to-book ratio is currently at 3.13, indicating how the market values the company's equity relative to its book value. With a 52-week low of USD 11.16, the recent high marks a notable recovery and growth trajectory for 10X Genomics. Investors and market observers will be keen to monitor how the company continues to navigate the competitive landscape of the biotechnology industry.